StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.90 | $0.87 | -4.07% | 0.2M |
| 05-12 | $0.87 | $0.86 | -1.55% | 0.1M |
| 05-13 | $0.88 | $0.90 | +2.48% | 0.1M |
| 05-14 | $0.91 | $0.90 | -1.37% | 0.3M |
| 05-15 | $0.89 | $0.85 | -4.74% | 0.1M |
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $28.00K | $28.00K | $27.00K |
Operating Income | $-3.95M | $-13.48M | $-10.03M | $-6.61M |
Net Income | $-2.56M | $-14.29M | $-10.52M | $-3.49M |
EPS (Diluted) | $-0.04 | $-0.34 | $-0.31 | $-0.20 |
Total Assets | $30.16M | $29.72M | $30.74M | $16.52M |
Total Liabilities | $11.68M | $12.68M | $11.56M | $9.89M |
Cash & Equivalents | $3.82M | $5.89M | $3.46M | $6.79M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 50.05M | 49.33M | 45.59M | 20.52M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.